Hypofractionated radiation therapy alone for human papillomavirus-related oropharyngeal cancer.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-07 DOI:10.1002/hed.27908

Allen M Chen, Jeremy P Harris, Tjoson Tjoa, Yarah Haidar, William B Armstrong

{"title":"Hypofractionated radiation therapy alone for human papillomavirus-related oropharyngeal cancer.","authors":"Allen M Chen, Jeremy P Harris, Tjoson Tjoa, Yarah Haidar, William B Armstrong","doi":"10.1002/hed.27908","DOIUrl":null,"url":null,"abstract":"Purpose: To report a single-institutional experience with hypofractionated radiation therapy alone for human papillomavirus (HPV)-positive oropharyngeal cancer.Methods and materials: A total of 101 consecutive patients were treated by radiation therapy alone using a regimen of 66 Gy in 30 fractions (60 patients) or 70 Gy in 33 fractions (41 patients) for newly diagnosed p16-positive squamous cell carcinoma of the oropharynx. Sixty-seven patients (67%) were never smokers.Results: The 3-year actuarial rates of overall survival, local-regional control, and progression-free survival were 94%, 93%, and 89%, respectively. Among never-smokers, the 3-year rates of overall survival and local-regional control were 98% and 100%, respectively. The grade 3+ acute toxicity rate was 21%, with the most commonly observed side effects related to mucositis.Conclusion: Hypofractionated radiation alone resulted in excellent outcomes for patients with HPV-positive oropharyngeal cancer. A prospective clinical trial investigating this modality in the setting of de-escalation is currently underway.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27908","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To report a single-institutional experience with hypofractionated radiation therapy alone for human papillomavirus (HPV)-positive oropharyngeal cancer.

Methods and materials: A total of 101 consecutive patients were treated by radiation therapy alone using a regimen of 66 Gy in 30 fractions (60 patients) or 70 Gy in 33 fractions (41 patients) for newly diagnosed p16-positive squamous cell carcinoma of the oropharynx. Sixty-seven patients (67%) were never smokers.

Results: The 3-year actuarial rates of overall survival, local-regional control, and progression-free survival were 94%, 93%, and 89%, respectively. Among never-smokers, the 3-year rates of overall survival and local-regional control were 98% and 100%, respectively. The grade 3+ acute toxicity rate was 21%, with the most commonly observed side effects related to mucositis.

Conclusion: Hypofractionated radiation alone resulted in excellent outcomes for patients with HPV-positive oropharyngeal cancer. A prospective clinical trial investigating this modality in the setting of de-escalation is currently underway.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

人类乳头瘤病毒相关口咽癌的单纯低分次放射治疗。

目的：报告单个机构对人乳头状瘤病毒（HPV）阳性口咽癌进行低分次放射治疗的经验：对新确诊的 p16 阳性口咽鳞状细胞癌，共对 101 例连续患者进行了单独放疗，采用 66 Gy 分 30 次放疗（60 例患者）或 70 Gy 分 33 次放疗（41 例患者）的方案。67名患者（67%）从未吸烟：3年总生存率、局部区域控制率和无进展生存率的精算率分别为94%、93%和89%。在从不吸烟者中，3年总生存率和局部区域控制率分别为98%和100%。3级以上急性毒性发生率为21%，最常见的副作用与粘膜炎有关：结论：对于HPV阳性口咽癌患者来说，单纯低分次放射治疗的疗效非常好。目前正在进行一项前瞻性临床试验，研究这种模式在降级治疗中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊